SOX2 and asthma: Inhibiting FGFR1 has been shown to downregulate the expression of genes associated with asthma pathogenesis, including SOX2, a marker of epithelial-mesenchymal transition (EMT), as well as the mesenchymal markers N-cadherin and Vimentin (Wang K. et al., 2018).